Literature DB >> 10665515

Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits.

G E Barnes1, B Li, T Dean, M L Chandler.   

Abstract

OBJECTIVES: Using a three-way crossover study design, we compared the effects of brinzolamide 2%, dorzolamide 2%, and placebo (vehicle) on microvascular optic nerve head (ONH) blood flow, intraocular pressure (IOP), blood pressure, heart rate, and acid-base balance in nine acepromazine-tranquilized Dutch-belted rabbits.
METHODS: Baseline measurements were taken before treatment and after drug-free washout periods of 7-14 days. Microvascular ONH blood flow was measured with a fundus camera-based laser Doppler flowmeter (LDF). Intraocular pressure was measured with a Tono-Pen XL. One drop of brinzolamide, dorzolamide, or vehicle was administered twice daily (9 A.M. and 5 P.M.) in right eyes only for 7 days. Experimental measurements were made 90 minutes after the 9 A.M. topical dose was administered on day 8.
RESULTS: ONH blood flow was significantly increased (P< or =0.05) in carbonic anhydrase inhibitor (CAI)-treated rabbits, as compared with vehicle-treated controls. The percent increase from baseline was 11.2+/-1.8% in brinzolamide-treated animals and 8.4+/-4.3% in dorzolamide-treated animals. Compared with controls, IOP in the brinzolamide- and dorzolamide-treated groups was significantly decreased (P< or =0.05). The changes in ONH blood flow and IOP were not significantly different between the CAI treatment groups. Small but significant changes in systemic blood gas tensions and pH were present in both CAI treatment groups, as compared with the vehicle group. Systemic blood pressure and heart rate were not significantly changed.
CONCLUSIONS: Topical ocular CAI treatment for 1 week with either brinzolamide or dorzolamide significantly reduced IOP and significantly increased ONH blood flow in tranquilized Dutch-belted rabbits, while eliciting minimal systemic acid-base balance disturbances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665515     DOI: 10.1016/s0039-6257(99)00124-1

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  11 in total

Review 1.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

2.  Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.

Authors:  Rajendra S Kadam; Gajanan Jadhav; Miller Ogidigben; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2011-06-14       Impact factor: 3.922

Review 3.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

4.  Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits.

Authors:  Herbert A Reitsamer; Barbara Bogner; Birgit Tockner; Jeffrey W Kiel
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-31       Impact factor: 4.799

5.  Effects of brinzolamide on ocular haemodynamics in healthy volunteers.

Authors:  M Kaup; N Plange; M Niegel; A Remky; O Arend
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

6.  A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients.

Authors:  Antonio Martínez; Manuel Sánchez-Salorio
Journal:  J Ocul Pharmacol Ther       Date:  2009-06       Impact factor: 2.671

7.  Effects of brinzolamide on rabbit ocular blood flow in vivo and ex vivo.

Authors:  Ya-Ru Dong; Shi-Wei Huang; Ji-Zhe Cui; Takeshi Yoshitomi
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

8.  Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension.

Authors:  Michele Iester
Journal:  Clin Ophthalmol       Date:  2008-09

9.  Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Henny J M Beckers; Jan Sag Schouten; Carroll A B Webers
Journal:  Clin Ophthalmol       Date:  2009-11-02

10.  Effects of Dorzolamide on Retinal and Choroidal Blood Flow in the DBA/2J Mouse Model of Glaucoma.

Authors:  Saurav Chandra; Eric R Muir; Kaiwalya Deo; Jeffrey W Kiel; Timothy Q Duong
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.